United Therapeutics Q3 revenue $748.9M (+23% YoY); net income $309.1M (+16%)

UNITED THERAPEUTICS Corp

2024-Q3 EPS reported $18.43 revenue$2,141,500,000

Total revenues $748.9M, +23% YoY; net income $309.1M ($6.39 diluted EPS) vs $267.6M ($5.38).
Tyvaso product revenues $433.8M, +33% YoY driven by Tyvaso DPI uptake and PH-ILD expansion.
Accrued $65.1M litigation liability related to ongoing Sandoz patent case; final judgment pending.
Completed $1B accelerated share repurchase; repurchased ~3.55M shares during Q2-Q3 2024.
Management notes record revenue sixth straight quarter; Tyvaso remains key growth driver.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.